# Heico Corp: financial statements, quarterly

HEI · NYSE · CIK 46619 · [Industrials](/sectors/industrials.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/hei.md) · [Financials](/companies/hei/financials.md) · [Filings](/companies/hei/filings.md) · [Insiders](/companies/hei/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hei/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [936 d](/filings/0000046619-25-000082.md) | [896](/filings/0000046619-25-000015.md) | [955](/filings/0000046619-25-000046.md) | [992](/filings/0000046619-25-000062.md) | [1,014 d](/filings/0000046619-25-000082.md) | [1,030](/filings/0000046619-26-000005.md) | [1,098](/filings/0000046619-26-000016.md) | [1,148](/filings/0000046619-26-000020.md) | [1,209 d](/filings/0000046619-25-000082.md) | [1,179](/filings/0000046619-26-000005.md) | [1,376](/filings/0000046619-26-000016.md) | [1,413](/filings/0000046619-26-000020.md) |
| Cost of revenue | $m | [572 d](/filings/0000046619-25-000082.md) | [550](/filings/0000046619-25-000015.md) | [584](/filings/0000046619-25-000046.md) | [603](/filings/0000046619-25-000062.md) | [620 d](/filings/0000046619-25-000082.md) | [625](/filings/0000046619-26-000005.md) | [660](/filings/0000046619-26-000016.md) | [690](/filings/0000046619-26-000020.md) | [724 d](/filings/0000046619-25-000082.md) | [724](/filings/0000046619-26-000005.md) | [806](/filings/0000046619-26-000016.md) | [832](/filings/0000046619-26-000020.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [27.3 d](/filings/0000046619-25-000082.md) | [25.1](/filings/0000046619-24-000014.md) | [27.9](/filings/0000046619-25-000046.md) | [29.8](/filings/0000046619-25-000062.md) | [28.5 d](/filings/0000046619-25-000082.md) | [27.6](/filings/0000046619-26-000005.md) | [28.7](/filings/0000046619-26-000016.md) | [31.9](/filings/0000046619-26-000020.md) | [32.7 d](/filings/0000046619-25-000082.md) | [31.9](/filings/0000046619-26-000005.md) | [36.4](/filings/0000046619-26-000016.md) | [36.1](/filings/0000046619-26-000020.md) |
| Selling, general and administrative | $m | [175 d](/filings/0000046619-25-000082.md) | [167](/filings/0000046619-25-000015.md) | [163](/filings/0000046619-25-000046.md) | [173](/filings/0000046619-25-000062.md) | [175 d](/filings/0000046619-25-000082.md) | [179](/filings/0000046619-26-000005.md) | [190](/filings/0000046619-26-000016.md) | [192](/filings/0000046619-26-000020.md) | [207 d](/filings/0000046619-25-000082.md) | [195](/filings/0000046619-26-000005.md) | [219](/filings/0000046619-26-000016.md) | [226](/filings/0000046619-26-000020.md) |
| Operating income | $m | [189 d](/filings/0000046619-25-000082.md) | [180](/filings/0000046619-25-000015.md) | [209](/filings/0000046619-25-000046.md) | [216](/filings/0000046619-25-000062.md) | [219 d](/filings/0000046619-25-000082.md) | [227](/filings/0000046619-26-000005.md) | [248](/filings/0000046619-26-000016.md) | [265](/filings/0000046619-26-000020.md) | [279 d](/filings/0000046619-25-000082.md) | [260](/filings/0000046619-26-000005.md) | [350](/filings/0000046619-26-000016.md) | [355](/filings/0000046619-26-000020.md) |
| Income tax | $m | [33.5 d](/filings/0000046619-25-000082.md) | [16.8](/filings/0000046619-25-000015.md) | [36.2](/filings/0000046619-25-000046.md) | [32.5](/filings/0000046619-25-000062.md) | [33.0 d](/filings/0000046619-25-000082.md) | [13.7](/filings/0000046619-26-000005.md) | [45.4](/filings/0000046619-26-000016.md) | [44.3](/filings/0000046619-26-000020.md) | [44.6 d](/filings/0000046619-25-000082.md) | [26.7](/filings/0000046619-26-000005.md) | [67.2](/filings/0000046619-26-000016.md) | [66.1](/filings/0000046619-26-000020.md) |
| Net income | $m | [103 d](/filings/0000046619-25-000082.md) | [115](/filings/0000046619-25-000015.md) | [123](/filings/0000046619-25-000046.md) | [137](/filings/0000046619-25-000062.md) | [140 d](/filings/0000046619-25-000082.md) | [168](/filings/0000046619-26-000005.md) | [157](/filings/0000046619-26-000016.md) | [177](/filings/0000046619-26-000020.md) | [188 d](/filings/0000046619-25-000082.md) | [190](/filings/0000046619-26-000005.md) | [234](/filings/0000046619-26-000016.md) | [235](/filings/0000046619-26-000020.md) |
| Diluted EPS | $ per share | not reported | [0.82](/filings/0000046619-25-000015.md) | [0.88](/filings/0000046619-25-000046.md) | [0.97](/filings/0000046619-25-000062.md) | not reported | [1.20](/filings/0000046619-26-000005.md) | [1.12](/filings/0000046619-26-000016.md) | [1.26](/filings/0000046619-26-000020.md) | not reported | [1.35](/filings/0000046619-26-000005.md) | [1.66](/filings/0000046619-26-000016.md) | [1.67](/filings/0000046619-26-000020.md) |
| Basic EPS | $ per share | not reported | [0.83](/filings/0000046619-25-000015.md) | [0.89](/filings/0000046619-25-000046.md) | [0.99](/filings/0000046619-25-000062.md) | not reported | [1.21](/filings/0000046619-26-000005.md) | [1.13](/filings/0000046619-26-000016.md) | [1.27](/filings/0000046619-26-000020.md) | not reported | [1.36](/filings/0000046619-26-000005.md) | [1.68](/filings/0000046619-26-000016.md) | [1.69](/filings/0000046619-26-000020.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [171](/filings/0000046619-24-000059.md) | [196](/filings/0000046619-24-000014.md) | [204](/filings/0000046619-24-000039.md) | [203](/filings/0000046619-24-000059.md) | [162](/filings/0000046619-25-000062.md) | [165](/filings/0000046619-25-000015.md) | [242](/filings/0000046619-25-000046.md) | [262](/filings/0000046619-25-000062.md) | [218](/filings/0000046619-26-000020.md) | [261](/filings/0000046619-26-000005.md) | [210](/filings/0000046619-26-000016.md) | [241](/filings/0000046619-26-000020.md) |
| Current assets | $m | [1,855](/filings/0000046619-24-000111.md) | [1,912](/filings/0000046619-24-000014.md) | [1,969](/filings/0000046619-24-000039.md) | [2,027](/filings/0000046619-24-000059.md) | [2,062](/filings/0000046619-25-000082.md) | [2,103](/filings/0000046619-25-000015.md) | [2,283](/filings/0000046619-25-000046.md) | [2,386](/filings/0000046619-25-000062.md) | [2,356](/filings/0000046619-26-000020.md) | [2,480](/filings/0000046619-26-000005.md) | [2,636](/filings/0000046619-26-000016.md) | [2,725](/filings/0000046619-26-000020.md) |
| Total assets | $m | [7,195](/filings/0000046619-24-000111.md) | [7,336](/filings/0000046619-24-000014.md) | [7,366](/filings/0000046619-24-000039.md) | [7,422](/filings/0000046619-24-000059.md) | [7,593](/filings/0000046619-25-000082.md) | [7,891](/filings/0000046619-25-000015.md) | [8,092](/filings/0000046619-25-000046.md) | [8,532](/filings/0000046619-25-000062.md) | [8,500](/filings/0000046619-26-000020.md) | [9,044](/filings/0000046619-26-000005.md) | [9,592](/filings/0000046619-26-000016.md) | [9,937](/filings/0000046619-26-000020.md) |
| Current liabilities | $m | [665](/filings/0000046619-24-000111.md) | [604](/filings/0000046619-24-000014.md) | [559](/filings/0000046619-24-000039.md) | [615](/filings/0000046619-24-000059.md) | [664](/filings/0000046619-25-000082.md) | [618](/filings/0000046619-25-000015.md) | [665](/filings/0000046619-25-000046.md) | [711](/filings/0000046619-25-000062.md) | [832](/filings/0000046619-26-000020.md) | [811](/filings/0000046619-26-000005.md) | [904](/filings/0000046619-26-000016.md) | [1,003](/filings/0000046619-26-000020.md) |
| Total liabilities | $m | [3,637](/filings/0000046619-24-000111.md) | [3,654](/filings/0000046619-24-000014.md) | [3,555](/filings/0000046619-24-000039.md) | [3,496](/filings/0000046619-24-000059.md) | [3,529](/filings/0000046619-25-000082.md) | [3,656](/filings/0000046619-25-000015.md) | [3,620](/filings/0000046619-25-000046.md) | [3,882](/filings/0000046619-25-000062.md) | [3,654](/filings/0000046619-26-000020.md) | [3,998](/filings/0000046619-26-000005.md) | [4,201](/filings/0000046619-26-000016.md) | [4,294](/filings/0000046619-26-000020.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [4.3](/filings/0000046619-24-000111.md) | [4.7](/filings/0000046619-24-000014.md) | [4.4](/filings/0000046619-24-000039.md) | [4.2](/filings/0000046619-24-000059.md) | [4.1](/filings/0000046619-25-000082.md) | [4.0](/filings/0000046619-25-000015.md) | [3.8](/filings/0000046619-25-000046.md) | [3.7](/filings/0000046619-25-000062.md) | [3.4](/filings/0000046619-26-000020.md) | [3.4](/filings/0000046619-26-000005.md) | [3.4](/filings/0000046619-26-000016.md) | [3.5](/filings/0000046619-26-000020.md) |
| Shareholders' equity | $m | [3,146](/filings/0000046619-24-000111.md) | [3,266](/filings/0000046619-24-000014.md) | [3,389](/filings/0000046619-24-000039.md) | [3,540](/filings/0000046619-24-000059.md) | [3,637](/filings/0000046619-25-000082.md) | [3,747](/filings/0000046619-25-000015.md) | [3,968](/filings/0000046619-25-000046.md) | [4,141](/filings/0000046619-25-000062.md) | [4,305](/filings/0000046619-26-000020.md) | [4,503](/filings/0000046619-26-000005.md) | [4,772](/filings/0000046619-26-000016.md) | [4,948](/filings/0000046619-26-000020.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [148 d](/filings/0000046619-25-000082.md) | [112](/filings/0000046619-25-000015.md) | [141 d](/filings/0000046619-25-000046.md) | [214 d](/filings/0000046619-25-000062.md) | [206 d](/filings/0000046619-25-000082.md) | [203](/filings/0000046619-26-000005.md) | [205 d](/filings/0000046619-26-000016.md) | [231 d](/filings/0000046619-26-000020.md) | [295 d](/filings/0000046619-25-000082.md) | [179](/filings/0000046619-26-000005.md) | [292 d](/filings/0000046619-26-000016.md) | [345 d](/filings/0000046619-26-000020.md) |
| Capital expenditure | $m | [15.3 d](/filings/0000046619-25-000082.md) | [13.4](/filings/0000046619-25-000015.md) | [12.9 d](/filings/0000046619-25-000046.md) | [15.9 d](/filings/0000046619-25-000062.md) | [16.1 d](/filings/0000046619-25-000082.md) | [17.3](/filings/0000046619-26-000005.md) | [16.0](/filings/0000046619-26-000016.md) | [12.7 d](/filings/0000046619-26-000020.md) | [26.8 d](/filings/0000046619-25-000082.md) | [13.5](/filings/0000046619-26-000005.md) | [18.1](/filings/0000046619-26-000016.md) | [22.6 d](/filings/0000046619-26-000020.md) |
| Dividends paid | $m | [0.0 d](/filings/0000046619-25-000082.md) | [13.8](/filings/0000046619-25-000015.md) | [0.0 d](/filings/0000046619-25-000046.md) | [15.2 d](/filings/0000046619-25-000062.md) | [0.0 d](/filings/0000046619-25-000082.md) | [15.3](/filings/0000046619-26-000005.md) | [0.0 d](/filings/0000046619-26-000016.md) | [16.7 d](/filings/0000046619-26-000020.md) | [0.0 d](/filings/0000046619-25-000082.md) | [16.7](/filings/0000046619-26-000005.md) | [0.0 d](/filings/0000046619-26-000016.md) | [18.2 d](/filings/0000046619-26-000020.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [139](/filings/0000046619-24-000014.md) | [139](/filings/0000046619-24-000039.md) | [139](/filings/0000046619-24-000059.md) | [140](/filings/0000046619-25-000015.md) | [140](/filings/0000046619-25-000046.md) | [140](/filings/0000046619-25-000062.md) | [140](/filings/0000046619-26-000005.md) | [141](/filings/0000046619-26-000016.md) | [141](/filings/0000046619-26-000020.md) | [141](/filings/0000046619-26-000005.md) | [141](/filings/0000046619-26-000016.md) | [141](/filings/0000046619-26-000020.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,905,966 at 2015-12-15, from the cover of the [10-K filed 2015-12-17](/filings/0000046619-15-000078.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:18 ET. No prices; not investment advice.